named programs · 3 · from sources
What they call their work
Children Can’t Wait Campaign
Fundraising and awareness initiative to support the development of pediatric treatments and devices for rare diseases, emphasizing urgency and collective action.
CobiCure Impact Series
Annual convening of scientists, investors, clinicians, and advocates to accelerate innovation in pediatric rare disease treatments; inaugural event held February 25, 2026 in New York City.
Pediatric Therapeutic Acceleration Program
Initiative to de-risk and advance promising pediatric medical devices and therapies from discovery through early development, particularly for rare diseases lacking commercial incentives.
activities · 5 groups
What they do
-
Biomedical Research and Innovation 2 activities
- Building capacity in pediatric healthcare innovationDevelops expertise and collaborative networks to advance solutions for underserved communities in pediatric healthcare, including launching a fellowship program and participating in the ARPA-H Investor Catalyst Hub Spoke Network to strengthen innovation ecosystems.
- Developing pediatric medical devices and drug therapiesAdvances pediatric medical devices and drug therapies through partnerships with industry, experts, and philanthropic organizations, focusing on early-stage innovation and unmet needs in pediatric and rare diseases. Activities include de-risking technologies for clinical application and expanding a portfolio of treatments for pediatric populations.
-
-
Rare Genetic Disease Research and Advocacy 1 activity
- Conducting and catalyzing research for rare and pediatric conditionsSupports and drives research initiatives that develop new approaches for treating rare congenital disorders and pediatric diseases, including catalyzing research on SARM1 inhibitors for rare eye diseases and advancing therapeutic programs through donated funding.
-
-
Genetic and Neurological Disease Research Funding 1 activity
- Funding research and development of pediatric and rare disease therapeuticsProvides grants and funding to accelerate research, early clinical development, and clinical collaborations for pediatric medical devices and therapeutics, including support for clinical trials and development-to-market pathways. Includes funding for specific research on rare diseases such as ADOA and retinoblastoma.
-
-
Patient and Researcher Conferences 1 activity
- Hosting impact events to advance pediatric innovationOrganizes and hosts events such as the Impact Series to convene stakeholders and accelerate pediatric innovation, exemplified by the February 25, 2026 event in New York City titled "Children Can’t Wait."
-
-
Uncategorized 1 activity
- Operating a hybrid healthcare innovation organizationRuns a charitable organization that combines for-profit leadership and infrastructure with non-profit mission goals to eliminate healthcare barriers, particularly in pediatric and rare disease innovation.
-
financials · form 990 · fy2024
revenue
Total revenue$1.08M
Contributions & grants$13.70M1265%
Program service revenue$00%
Investment income$-12.61M-1165%
Other revenue$0
expenses
Total expenses$7.14M
Program expenses70%
Admin / overhead25%
Fundraising5%
Salaries & benefits$2.31M
Grants paid out$1.88M
Largest expense lineCompensation
balance sheet
Total assets$4.79M
Cash$3.79M
Investments$497K
Liabilities$367K
Net assets$4.42M
Liquid reserves7.2 mo
4 years on record · 2021–2024 · YoY revenue -93.6%
leadership · form 990 part vii · fy2024
Who runs it
paid leadership · 7
| Name | Title | Hours/wk | Compensation |
|---|---|---|---|
| MICHELE CLEARY DIR TO 524 | CHIEF SCIENTIFIC OFFICER (AS OF 6/24) | 40 | $333K |
| EMMA MORAN EVANS | DIRECTOR, COBICURE MED TECH | 40 | $331K |
| MAUREEN REYES | DIRECTOR, STRATEGY & OPS | 40 | $318K |
| ROBERT OLAN | VP BUSINESS DEVELOPMENT | 40 | $294K |
| LINDSEY REYNOLDS | DIRECTOR, FINANCE | 40 | $289K |
| SHAWN DAVIS TO 224 | SVP & COO | 40 | $252K |
| JYOTI PATEL | DIRECTOR BUSINESS OPS & MARKETING | 40 | $234K |
board members · 7
- GARY BREWSTER AS OF 424 — DIRECTOR
- JEFFREY KAPLAN TO 424 — TREASURER
- LAURIE ZEPHYRIN — DIRECTOR
- MARK VEICH — PRESIDENT
- OLIVIER ELEMENTO — SECRETARY
- RON MITCHELL — DIRECTOR
- YUNG LIE AS OF 624 — DIRECTOR
relationships · 30
Who they work with
- ARPA-H Network — Member of the ARPA-H Investor Catalyst Hub Spoke Network.
- Aileron Therapeutics Partner — Collaborates on an exclusive option agreement for the acquisition of ALRN-6924 for retinoblastoma.
- Asha Therapeutics Partner — Collaborated with Advancium Health Network on grant-funded research for a SARM1 inhibitor targeting ADOA.
- Boston Children's Hospital Partner — Partnered with Advancium Health Network on preclinical research for a potential ADOA treatment.
- BrYet US Partner — Organization where Gary Brewster serves as Chief Financial Officer, providing financial leadership experience to Advancium Health Network.
- Break into the Boardroom Partner — Partner organization empowering women to attain leadership roles in healthcare.
- Bristol Myers Squibb Government — Dr. Cleary held a senior leadership role at Bristol Myers Squibb prior to joining Advancium.
- CC Therapeutics Partner — Partner organization focused on reimagining pediatric drug development.
- CobiCure Partner — Non-profit company affiliated with Advancium Health Network focused on rare cancer research and advocacy.
- CobiCure MedTech Partner — Partner organization focused on reimagining pediatric medical device development.
- Damon Runyon Cancer Research Foundation Partner — Collaborative relationship through shared board leadership and aligned approaches to funding high-risk, high-impact science.
- Deerfield Partner — Founding partner providing scientific expertise, industry networks, and support to accelerate pediatric rare disease treatment development.
- Deerfield Partner — Member of the biotech community with which Advancium has connections to support platform development.
- Deerfield Discovery and Development Partner — Dr. Cleary led academic partnerships for Deerfield Discovery and Development, the internal R&D engine of Deerfield Management.
- Deerfield Foundation Partner — Co-launcher and founding partner of Advancium Health Network
- Deerfield Management Partner — Board members Howard Furst, M.D., and Michael Hurley, M.D., are Partner and Principal, respectively, at Deerfield Management, indicating a strategic affiliation with the healthcare investment firm.
- Deerfield Management Partner — Co-launcher and founding partner of Advancium Health Network
- Deerfield Management Partner — Launched Advancium Health Network.
- Deerfield Management Partner — Leverages Deerfield Management’s healthcare and life science innovation ecosystem to accelerate pediatric medical solutions.
- Deerfield Management Company Partner — Launched Advancium Health Network and supports its mission to advance philanthropy in healthcare.
- Iron Triangle Partners LP Funder — Healthcare investment firm whose support helped enable Advancium Health Network's grants for ADOA research.
- Jefferies, LLC Partner — Board member Philip Ross, M.D., is Vice Chairman of Investment Banking and Global Chairman, Healthcare at Jefferies, LLC, indicating a leadership-level affiliation.
- Low Post Ventures Partner — Ron Mitchell, Managing Partner at Low Post Ventures, is a member of Advancium’s Board of Directors, indicating a governance and strategic partnership.
- LukaShai Foundation Partner — Partner organization conducting research to support families facing rare congenital disorders.
- Mark Foundation for Cancer Research Partner — Dr. Cleary launched the Mark Foundation for Cancer Research as its first CEO.
- Maxine and Stuart Frankel Foundation Funder — Provided $30 million in funding to support Advancium Health Network’s initiatives.
- Merck Research Laboratories Government — Dr. Cleary held a senior leadership role at Merck Research Laboratories prior to joining Advancium.
- St. Jude Children’s Research Hospital Partner — Collaborates through clinical leadership and innovative trial design approaches to advance pediatric rare disease research.
- The Maxine and Stuart Frankel Foundation Funder — Provided a $10 million grant to establish the Maxine and Stuart Frankel Accelerator and deepen collaboration with Advancium.
- The Maxine and Stuart Frankel Foundation Funder — Provided philanthropic support enabling Advancium Health Network's grants for ADOA research.
strategies · 5
How they approach the work
Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.
- Collaborative Innovation Networkmethodology: collaborative_innovation_networkBy uniting philanthropists, researchers, clinicians, industry partners, and technology experts in a shared ecosystem, the organization accelerates pediatric health innovation because collective expertise and aligned resources increase the speed and quality of therapeutic development.
- Hybrid Nonprofit-For-Profit Modelmethodology: hybrid_nonprofit_forprofit_modelBy combining for-profit infrastructure and expertise with nonprofit mission-driven goals, the organization overcomes systemic barriers in healthcare access and innovation, enabling scalable and sustainable development of pediatric and rare disease therapies because this model leverages efficiency and risk tolerance from both sectors.
- Philanthropic Bridge to Commercializationmethodology: philanthropic_bridge_to_commercializationBy using philanthropic capital to advance rare disease therapies through early development stages, then transitioning them to commercial partners, the organization de-risks and accelerates the path to scale because it treats philanthropy as a force multiplier rather than a temporary bridge.
- Risk-Tolerant Science Fundingmethodology: risk-tolerant_science_fundingBy investing in high-risk, high-reward research and prioritizing scientific discovery over immediate commercial returns, the organization generates critical learning and advances rare disease therapies because it allows researchers flexibility to pursue breakthroughs even when failure is possible.
- Targeted Gap Fundingmethodology: targeted_gap_fundingBy identifying and addressing critical funding gaps in rare disease and pediatric research, the organization directs resources to the highest-need areas because focused investment in underfunded stages of development increases the likelihood of clinical success.